Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Amortization of Deferred Charges: 2024-2025

Historic Amortization of Deferred Charges for Arrowhead Pharmaceuticals (ARWR) over the last 1 years, with Sep 2025 value amounting to $14.6 million.

  • Arrowhead Pharmaceuticals' Amortization of Deferred Charges rose 56.18% to $14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.3 million, marking a year-over-year change of. This contributed to the annual value of $63.3 million for FY2025, which is 579.67% up from last year.
  • Arrowhead Pharmaceuticals' Amortization of Deferred Charges amounted to $14.6 million in Q3 2025, which was down 11.30% from $16.4 million recorded in Q2 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Amortization of Deferred Charges peaked at $16.4 million during Q2 2025, and registered a low of $9.3 million during Q3 2024.
  • Over the past 2 years, Arrowhead Pharmaceuticals' median Amortization of Deferred Charges value was $16.1 million (recorded in 2025), while the average stood at $14.5 million.
  • Data for Arrowhead Pharmaceuticals' Amortization of Deferred Charges shows a peak YoY skyrocketed of 56.18% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Arrowhead Pharmaceuticals' Amortization of Deferred Charges stood at $16.2 million in 2024, then skyrocketed by 56.18% to $14.6 million in 2025.
  • Its last three reported values are $14.6 million in Q3 2025, $16.4 million for Q2 2025, and $16.1 million during Q1 2025.